Objectives: To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice. Methods: Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA. Results: No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse. Conclusions: PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giantcell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.
|Number of pages||3|
|Journal||Clinical and Experimental Rheumatology|
|Publication status||Published - 2010|
- Biological marker
- Polymyalgia reumatica
ASJC Scopus subject areas
- Immunology and Allergy